Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 15, 2020October 15, 2020

First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC

News

The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the ... Read more

September 29, 2020September 29, 2020

STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer

News

Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients ... Read more

August 27, 2020August 27, 2020

First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial

News

The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, ... Read more

June 16, 2020June 16, 2020

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

News

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, ... Read more

June 9, 2020June 9, 2020

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

News

VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase ... Read more

April 1, 2020April 1, 2020

Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending

News

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of ... Read more

March 20, 2020March 20, 2020

China Reviewing Zejula as First-line Therapy for Ovarian Cancer

News

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding ... Read more

March 4, 2020March 4, 2020

DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show

News

Treatment with IMV‘s cancer vaccine DPX-Survivac, combined with intermittent low-dose cyclophosphamide, continues to show promise in women with recurrent, advanced ovarian cancer, updated results from a Phase 1/2 trial ... Read more

February 28, 2020February 28, 2020

COM701 Shows Promise in Treating Ovarian, Other Solid Tumors, Early Data Suggest

News

Treatment with Compugen‘s immune checkpoint inhibitor COM701, either alone or in combination with Opdivo (nivolumab), is well-tolerated in people with advanced solid tumors, including ovarian cancer, early Phase 1 trial results ... Read more

February 26, 2020February 27, 2020

Zejula as First-line Treatment for Advanced Ovarian Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has accepted GSK‘s request to extend approval for Zejula (niraparib) to include as a first-line maintenance therapy for women with newly diagnosed ... Read more